Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC diaper rash products

This article was originally published in The Tan Sheet

Executive Summary

Compliance bulletin issued to the field on May 21 notes that "the use of any active external analgesic ingredient and/or topical antifungal ingredient in a product offered to treat and/or prevent diaper rash introduced . . . into interstate commerce" after June 17 without an approved NDA will be in violation of the FD&C Act. The final rules for external analgesics and topical antifungals used for diaper rash were published Dec. 18, 1992 and go into effect on June 18. The bulletin lists several products for diaper rash, including Fisons' Caldesene Medicated Powder and Ointment, Fleming's Impregon, Sween's Sween Cream, Macsil's Balmex Baby Powder, and Innotek's Bottom Better.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS081527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel